These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 31443653

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.
    Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():295-304. PubMed ID: 23836970
    [Abstract] [Full Text] [Related]

  • 5. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimizing inhaled corticosteroid use in patients with chronic obstructive pulmonary disease: assessing blood eosinophils, neutrophil-to-lymphocyte ratio, and mortality outcomes in US adults.
    Hu HS, Wang Z, Jian LY, Zhao LM, Liu XD.
    Front Immunol; 2023 Jun; 14():1230766. PubMed ID: 38035096
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL, Lin CH.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():2341-2348. PubMed ID: 27703344
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reported pneumonia in patients with COPD: findings from the INSPIRE study.
    Calverley PMA, Stockley RA, Seemungal TAR, Hagan G, Willits LR, Riley JH, Wedzicha JA, Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators.
    Chest; 2011 Mar; 139(3):505-512. PubMed ID: 20576732
    [Abstract] [Full Text] [Related]

  • 12. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH, Kim YS, Linton JA, Nam CM, Choi Y, Park EC.
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of eosinophils and neutrophils on clinical effects of ICS in COPD.
    Hartjes FJ, Vonk JM, Faiz A, Hiemstra PS, Lapperre TS, Kerstjens HAM, Postma DS, van den Berge M, Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study Group.
    Respirology; 2018 Nov; 23(11):1023-1031. PubMed ID: 29696728
    [Abstract] [Full Text] [Related]

  • 14. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
    Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM.
    Ann Am Thorac Soc; 2015 Jan; 12(1):27-34. PubMed ID: 25490706
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F.
    Respir Res; 2015 Apr 23; 16(1):52. PubMed ID: 25899176
    [Abstract] [Full Text] [Related]

  • 16. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J.
    Eur Respir J; 2009 Sep 23; 34(3):641-7. PubMed ID: 19443528
    [Abstract] [Full Text] [Related]

  • 17. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM.
    Lancet Respir Med; 2016 May 23; 4(5):390-8. PubMed ID: 27066739
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
    Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A, Salford Lung Study Investigators.
    N Engl J Med; 2016 Sep 29; 375(13):1253-60. PubMed ID: 27593504
    [Abstract] [Full Text] [Related]

  • 19. Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials.
    Rubin DB, Ahmad HA, O'Neal M, Bennett S, Lettis S, Galkin DV, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2018 Sep 29; 13():189-201. PubMed ID: 29386888
    [Abstract] [Full Text] [Related]

  • 20. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M, Novelli F, Vagaggini B, Braido F, Papi A, Sanduzzi A, Santus P, Scichilone N, Paggiaro P.
    Pulm Pharmacol Ther; 2015 Feb 29; 30():44-50. PubMed ID: 25445928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.